

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-32) PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
1107-3 DIVSERIAL NO.  
10/601,940INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Sosnowski, et al.CUSTOMER NO.  
33769

(Use several sheets if necessary)

FILING DATE  
June 23, 2003GROUP ART UNIT  
Unassigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
AC	—	5,866,585	2/2/99	Fogel			
AC	—	6,054,128	4/25/00	Wakat			
AC	—	5,922,773	7/13/99	Lipton et al.			
AC	—	6,025,369	2/15/00	Rosenquist et al.			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
AC	—	WO 00/37087 A1	6/29/00	PCT				


## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AC	—	Bucci, L.R., FDA filing reference, August 27, 1999, pp. 1 and 2.
AC	—	Pei I. Ho et al., <i>Multiple Aspects of Homocysteine Neurotoxicity: Glutamate Excitotoxicity, Kinase Hyperactivation and DNA Damage</i> , Journal of Neuroscience Research 70:694-702 (December, 2002).

EXAMINER /Abigail Cotton/ (06/26/2006) DATE CONSIDERED 06/28/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 (Rev. 2-32) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 1107-3 DIV	SERIAL NO. 10/601,940
	APPLICANT Sosnowski, et al.	CUSTOMER NO. 33769
	FILING DATE June 23, 2003	GROUP ART UNIT Unassigned



AC	<input checked="" type="checkbox"/>	Seshadri, S. et al., <i>Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease</i> , 1: N Engl J Med. 2002 Feb 14; 346(7):476-83.
AC	<input checked="" type="checkbox"/>	Fonseca, V.A. et al., <i>Insulin Sensitivity and Plasma Homocysteine Concentrations in Non-Diabetic Obese and Normal Weight Subjects</i> , Atherosclerosis, 2003 March; 167(1):105-9.
*	<input type="checkbox"/>	A. Ambrosch et al., <i>Relation Between Homocysteinaemia and Diabetic Neuropathy in Patients with Type 2 Diabetes</i> , Diabetic Medicine, Volume 18, Issue 3, p.185, March 2001.
AC	<input checked="" type="checkbox"/>	Pamela Moore et al., <i>Apoptotic Cell Death in the Mouse Retinal Ganglion Cell Layer is Induced in Vivo by the Excitatory Amino Acid Homocysteine</i> , Exp Eye Res. 73(1), pp. 45-57, July, 2001, Academic Press.
AC	<input checked="" type="checkbox"/>	Centrum references, Whitehall Robins: <i>Centrum Focused Formulas Heart and Centrum Herbals Ginkgo</i> , from www.centrum.com.
AC	<input checked="" type="checkbox"/>	McCully, Kilmer S., M.D., <i>The Homocysteine Revolution "A Bold New Approach to the Prevention of Heart Disease"</i> , Keats Publishing, Los Angeles 1997, pp. 33, 64-65, 92-105, 137, 181.
AC	<input checked="" type="checkbox"/>	Bleich S., Degner, D., Bandelow, B., von Ahsen, N., Ruther, E., Kornhuber, J., <i>Plasma Homocysteine is a Predictor of Alcohol Withdrawal Seizures</i> , Neuroreport 2000, Aug. 21 Abstract.

\* This reference has not been considered because no copy has been provided by Applicants.

EXAMINER /Abigail Cotton/ (DATE CONSIDERED 06/28/2006)

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.